Empresa Northwest Biotherapeutics, Inc Nasdaq
Acciones
US66737P6007
Biotecnología e investigación médica
Resumen de negocios
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Immunotherapies for Cancer
100,0
%
| 2 | 100,0 % | 2 | 100,0 % | +14,80 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States, Germany, United Kingdom and Netherlands
100,0
%
| 2 | 100,0 % | 2 | 100,0 % | +14,80 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Alton L. Boynton
FOU | Founder | 79 | 18/03/96 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/01/00 |
David Innes
IRC | Investor Relations Contact | - | 26/02/19 |
General Counsel | 78 | 01/06/11 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 18/03/96 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Navid Malik
BRD | Director/Board Member | 55 | 01/04/12 |
Director/Board Member | 74 | 27/01/16 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 1 200 000 | 0 | 0 | 90,82 % |
Acción B | 1 | 1 208 177 416 | 1 097 287 981 ( 90,82 %) | 0 |
Información de la empresa
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane Suite 800
20814, Bethesda
+240 497 9024
http://www.nwbio.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+9,04 % | 114 mil M | |
+11,46 % | 104 mil M | |
-12,63 % | 22,41 mil M | |
-1,05 % | 22,28 mil M | |
-5,29 % | 19,07 mil M | |
-38,29 % | 18 mil M | |
-3,32 % | 17,89 mil M | |
+8,12 % | 14,28 mil M | |
+34,80 % | 12,55 mil M |